Related Articles: Valeant considers putting Egypt's Amoun up for grabs: Bloomberg Embattled Valeant doesn't 'need to sell anything,' new CEO says Valeant weighs sales of controversial heart meds, laggard Provenge: Bloomberg Valeant looks at what it might sell to raise cash: Reuters Valeant investors, shocked by lightweight guidance, aren't buying CEO Pearson's recovery plans Could a Bausch & Lomb IPO help save debt-laden Valeant? Ackman thinks so Valeant posts 36% growth amid pricing scrutiny; may sell neurology biz AstraZeneca seals the deal for Almirall's respiratory meds